EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Results From a Phase 4, Slow-Titration and Food Effect Trial to Assess the Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia

Jenna Hoogerheyde, David Walling, Kimball Johnson, Rachel Dyme, Allison Gaudy

BJPsych Open · 2026-06 · 12 (S1) · S400-S400

DOI: 10.1192/bjo.2026.11948 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJPsych Open, online erschienen am 30.06.2026. Verfasst von Jenna Hoogerheyde und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

In pharmacokinetic studies of xanomeline and trospium chloride (KarXT), dosing with food reduced trospium bioavailability, potentially impacting tolerability. This study was designed to demonstrate taking KarXT with food after a slow up-titration is safe and tolerable.

Methods

In pharmacokinetic studies of xanomeline and trospium chloride (KarXT), dosing with food reduced trospium bioavailability, potentially impacting tolerability. This study was designed to demonstrate taking KarXT with food after a slow up-titration is safe and tolerable.

Results

During periods 1 and 2, 64.2% and 39.0% of participants reported ≥1 treatment-emergent adverse event (TEAE), respectively. The most common TEAEs (≥5%) in period 1 were nausea (22.5%), dyspepsia (15.6%), headache (15.0%), constipation (12.7%), and vomiting (11.6%); the incidence of all new onset TEAEs was less in period 2 when taken with food. All TEAEs were mild or moderate in intensity; none were serious. PANSS total score decreased over periods 1 and 2; Clinical Global Impression-Severity score decreased over period 1 with no further change over period 2. Dose-normalized area under the curve and maximum plasma concentration of trospium pooled from cohorts 1 and 2 decreased by 36% and 43%, respectively, when taken with food versus fasting. No clinically significant differences were observed in xanomeline exposure.

Conclusion

After slow uptitration on an empty stomach, there was no increase in the incidence or severity of TEAEs when taking KarXT with food; efficacy was maintained.

Zitieren

APA

Hoogerheyde, J., Walling, D., Johnson, K., Dyme, R., & Gaudy, A. (2026). Results From a Phase 4, Slow-Titration and Food Effect Trial to Assess the Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia. BJPsych Open, 12(S1), S400-S400. https://doi.org/10.1192/bjo.2026.11948

Vancouver

Hoogerheyde J, Walling D, Johnson K, Dyme R, Gaudy A. Results From a Phase 4, Slow-Titration and Food Effect Trial to Assess the Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia. BJPsych Open. 2026;12(S1):S400-S400. doi:10.1192/bjo.2026.11948

BibTeX
@article{Hoogerheyde2026,
  author = {Hoogerheyde, Jenna and Walling, David and Johnson, Kimball and Dyme, Rachel and Gaudy, Allison},
  title = {Results From a Phase 4, Slow-Titration and Food Effect Trial to Assess the Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia},
  journal = {BJPsych Open},
  year = {2026},
  volume = {12},
  number = {S1},
  pages = {S400--S400},
  doi = {10.1192/bjo.2026.11948}
}
Kostenlos starten →